Thomas Hofmann

ORCID: 0000-0002-1389-6374
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cystic Fibrosis Research Advances
  • Inhalation and Respiratory Drug Delivery
  • Mycobacterium research and diagnosis
  • Asthma and respiratory diseases
  • Tuberculosis Research and Epidemiology
  • Neonatal Respiratory Health Research
  • Olfactory and Sensory Function Studies
  • Influenza Virus Research Studies
  • Quinazolinone synthesis and applications
  • Ion Transport and Channel Regulation
  • Antibiotic Resistance in Bacteria
  • Infectious Diseases and Mycology
  • Pneumonia and Respiratory Infections
  • Zoonotic diseases and public health
  • Antibiotics Pharmacokinetics and Efficacy
  • Bacillus and Francisella bacterial research
  • interferon and immune responses
  • Antimicrobial Resistance in Staphylococcus
  • Pediatric health and respiratory diseases
  • Nosocomial Infections in ICU
  • Yersinia bacterium, plague, ectoparasites research
  • Immune Response and Inflammation
  • Respiratory and Cough-Related Research
  • Analytical Chemistry and Chromatography
  • Computational Drug Discovery Methods

MannKind Corporation (United States)
2023

Hesse (Germany)
2014

Vectura (Germany)
2014

Micropharma (Canada)
2012

Discovery Laboratories (United States)
2008

Justus-Liebig-Universität Gießen
1997-1999

University of North Carolina at Chapel Hill
1998-1999

Vancouver General Hospital
1981

University of British Columbia
1981

Active sodium absorption is the dominant mechanism of ion transport in airway epithelium, but its role pulmonary physiology and host defense unknown. To address this question, we studied function epithelial cells determined frequency symptoms patients with systemic pseudohypoaldosteronism, a salt-losing disorder caused by loss-of-function mutations genes for channel.

10.1056/nejm199907153410304 article EN New England Journal of Medicine 1999-07-15

Methicillin-resistant Staphylococcus aureus (MRSA) has become a significant acute and chronic respiratory pathogen. While vancomycin is effective against MRSA, its relatively poor penetration into lung secretions dose-limiting renal toxicity make it less in the setting. As inhaled administration of would overcome these limitations, we developed dry powder formulation suitable for inhalation (AeroVanc). Here, report phase I, single-dose, dose-escalating study aimed at demonstrating safety...

10.1128/aac.01776-19 article EN Antimicrobial Agents and Chemotherapy 2020-01-16

The raised nasal transepithelial potential difference (PD) in cystic fibrosis (CF) reflects accelerated active transport of Na+, and is inhibited by topical administration the Na+ channel blocker, amiloride. aim this study was to investigate dose-effect time course topically administered conductance inhibitors inhibit PD, including benzamil, an analog We measured magnitude drug inhibition [percent baseline PD ( Δ PD%)] duration defined as when had recovered 50% (effective = ET50). Amiloride...

10.1164/ajrccm.157.6.9709043 article EN American Journal of Respiratory and Critical Care Medicine 1998-06-01

Pulmonary nontuberculous mycobacteria (NTM) infection is recognized as a major global health concern due to its rising prevalence worldwide. As an opportunistic pathogen with increasing antibiotics resistance, prolonged systemic dosing multiple remains the primary treatment paradigm. These treatments, administered predominantly by oral or parenteral routes, often lead toxicity. A novel inhaled formulation of clofazimine may finally resolve issues toxicity, thereby providing for improved NTM...

10.1128/aac.01144-22 article EN cc-by Antimicrobial Agents and Chemotherapy 2023-01-17

This phase 2/3 randomised, parallel-group, placebo-controlled trial investigated oral corticosteroid (OCS)-sparing efficacy, safety and tolerability of nebulised budesonide (Bud) administered with a novel computer-controlled, compressor-driven inhalation system (AKITA) as add-on therapy to Global Initiative for Asthma step 5. Patients (18–65 years) OCS-dependent asthma were randomised (2:1:1:1) receive 18-week, twice-daily, double-blind treatment AKITA inhaled (AICS)-Bud 1 mg, AICS-Bud 0.5...

10.1183/09031936.00152014 article EN European Respiratory Journal 2014-12-10

Influenza has been a long-running health problem and novel antiviral drugs are urgently needed. In pre-clinical studies, we demonstrated broad activity of D, L-lysine-acetylsalicylate glycine (LASAG) against influenza virus (IV) in cell culture protection lethal challenge mice. LASAG is compound with new mode action. It inhibits the NF-κB signal transduction module that essential for IV replication. Our goal was to determine whether aerosolized would also show therapeutic benefit...

10.1038/s41426-018-0023-3 article EN cc-by Emerging Microbes & Infections 2018-03-05

Cystic fibrosis (CF) is associated with impaired ion transport across epithelial membranes and an increased transepithelial potential difference (PD) that can be measured in airway epithelium. The aim of this study was to investigate the diagnostic value nasal PD CF, test a modified approach measurement PD. reproducibility sensitivity specificity measurements were tested perfusion technique simplified modification done novel, solid-state exploring electrode. With method, basal values...

10.1164/ajrccm.155.6.9196094 article EN American Journal of Respiratory and Critical Care Medicine 1997-06-01

Three procedures (radioimmunoassay, fluorescence immunoassay, and enzyme immunoassay) for the determination of gentamicin tobramycin levels were compared. These systems evaluated on basis accuracy, reproducibility, specificity, cost. All three showed a high degree accuracy precision. The immunoassay gave significantly lower values at below 5 microgram/ml. Of systems, radioimmunoassay was least expensive, provided that minimum 10 analyses performed daily; single tests required more technical...

10.1128/aac.20.6.821 article EN Antimicrobial Agents and Chemotherapy 1981-12-01

The aerosolized application of surfactants has been explored in neonatal indications, such as respiratory distress syndrome (RDS) and adult asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD). However, the practical limited by many technical difficulties related to aerosol creation (foaming, low output rate) or inactivation surfactant. To date, no surfactant carried through preclinical clinical development. Using example developing lucinactant (“KL4-surfactant“) for...

10.1055/s-2008-1076101 article EN Pneumologie 2008-04-01
Coming Soon ...